Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia is a research paper published in New England Journal of Medicine (2024). On theSindex it has a DataRank of 1.3. It has been cited 61 times, with 40 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.619
From this paper's citation signal
Citation Network Contribution
0.693
From 13 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 40 citers.
NIDDK NIH HHS
Grant: T32 DK007245
Neurocrine Biosciences
Fields of Study
MeSH Terms